patidegib

Sponsor Sol-gel Technologies LTD. · listed as SLGL

READOUT Phase 3 Confidence: medium Source: clinicaltrials

patidegib is a clinical-stage drug asset sponsored by Sol-gel Technologies LTD., listed as SLGL. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 2026 (month precision, medium confidence), tied to trial NCT06050122. The asset is in Phase 3 and currently active not recruiting, studied in Gorlin Syndrome.

Next catalyst

Event typeREADOUT

Expected date2026-08-31

As disclosedAug 2026

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06050122

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorSol-Gel Technologies, Ltd.

Listed asSLGL

Condition(s)Gorlin Syndrome

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More SLGL catalysts